JW Shinyak Corporation (KOSDAQ:067290)

South Korea flag South Korea · Delayed Price · Currency is KRW
2,070.00
-10.00 (-0.48%)
At close: Apr 28, 2026
41.14%
Market Cap 114.26B
Revenue (ttm) 81.04B
Net Income (ttm) 15.66B
Shares Out 55.87M
EPS (ttm) 245.00
PE Ratio 8.35
Forward PE n/a
Dividend n/a
Ex-Dividend Date n/a
Volume 330,917
Average Volume 704,276
Open 2,090.00
Previous Close 2,080.00
Day's Range 2,040.00 - 2,120.00
52-Week Range 1,288.57 - 2,670.00
Beta 0.84
RSI 49.58
Earnings Date May 14, 2026

About JW Shinyak

JW Shinyak Corporation engages in the research, development, production, and sale of medicines and medical supplies in South Korea. It offers pharmaceutical products in the areas of dermatology, urology, pediatrics, otolaryngology, etc.; and cardiovascular, gastrointestinal, urinary, NSAIDs, antibiotics, anti-fungal, anti-viral, respiratory, antihistamines, steroid hormone, anti-obesity, and other products, as well as eye drops, and antitussives and expectorants. The company also develops prostate cancer treatment, liver cancer treatment, rheum... [Read more]

Industry Orthopedic, Prosthetic, and Surgical Appliances and Supplies
Founded 1981
Employees 183
Stock Exchange KOSDAQ
Ticker Symbol 067290
Full Company Profile

Financial Performance

In 2025, JW Shinyak's revenue was 81.04 billion, a decrease of -12.87% compared to the previous year's 93.01 billion. Earnings were 15.66 billion, an increase of 208.11%.

Financial Statements

News

There is no news available yet.